| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | acquired(M) | 25.3K | — | $0 |
| May 1, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | disposed(F) | 11.0K | $229.85 | $2.5M |
| May 1, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | disposed(M) | 25.3K | — | $0 |
| Apr 23, 2026 | MORIKIS JOHN G | Director | acquired(A) | 1.5K | — | $0 |
| Apr 23, 2026 | Pinto Daniel E | Director | acquired(A) | 1.7K | — | $0 |
| Apr 23, 2026 | HEWSON MARILLYN A | Director | acquired(A) | 975 | — | $0 |
| Apr 23, 2026 | McClellan Mark B. | Director | acquired(A) | 975 | — | $0 |
| Apr 23, 2026 | Johnson Paula A | Director | acquired(A) | 975 | — | $0 |
| Apr 23, 2026 | Joly Hubert | Director | acquired(A) | 975 | — | $0 |
| Apr 23, 2026 | West Nadja | Director | acquired(A) | 975 | — | $0 |
| Apr 23, 2026 | Beckerle Mary C | Director | acquired(A) | 975 | — | $0 |
| Apr 23, 2026 | Woods Eugene A. | Director | acquired(A) | 975 | — | $0 |
| Apr 23, 2026 | WEINBERGER MARK A | Director | acquired(A) | 975 | — | $0 |
| Apr 23, 2026 | Doudna Jennifer A | Director | acquired(A) | 975 | — | $0 |
| Mar 10, 2026 | Woods Eugene A. | Director | acquired(A) | 154.869 | $242.14 | $37K |
| Mar 10, 2026 | HEWSON MARILLYN A | Director | acquired(A) | 206.492 | $242.14 | $50K |
| Mar 10, 2026 | Pinto Daniel E | Director | acquired(A) | 129.058 | $242.14 | $31K |
| Feb 27, 2026 | Decker Robert J | VP Corporate Controller | acquired(M) | 4.1K | $115.67 | $471K |
| Feb 27, 2026 | Decker Robert J | VP Corporate Controller | disposed(M) | 4.1K | — | $0 |
| Feb 27, 2026 | Decker Robert J | VP Corporate Controller | Sell(S) | 4.1K | $247.87 | $1.0M |
| Feb 20, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell(S) | 1.3K | $245.66 | $325K |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | acquired(M) | 13.6K | $115.67 | $1.6M |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell(S) | 9.0K | $244.53 | $2.2M |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | disposed(M) | 9.0K | — | $0 |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | disposed(M) | 13.6K | — | $0 |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell(S) | 13.6K | $244.20 | $3.3M |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | acquired(M) | 9.0K | $129.51 | $1.2M |
| Feb 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | disposed(M) | 21.7K | — | $0 |
| Feb 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | disposed(M) | 29.9K | — | $0 |
| Feb 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell(S) | 2.3K | $243.00 | $555K |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | disposed(M) | 12.1K | — | $0 |
| Feb 17, 2026 | Swanson James D. | EVP, CIO | disposed(M) | 20.5K | — | $0 |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | acquired(M) | 12.1K | $129.51 | $1.6M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | acquired(M) | 19.2K | $115.67 | $2.2M |
| Feb 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell(S) | 21.7K | $243.00 | $5.3M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Sell(S) | 25.0K | $242.68 | $6.1M |
| Feb 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | acquired(M) | 21.7K | $157.92 | $3.4M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Sell(S) | 33.4K | $242.75 | $8.1M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | disposed(M) | 33.4K | — | $0 |
| Feb 17, 2026 | Swanson James D. | EVP, CIO | Sell(S) | 20.5K | $242.70 | $5.0M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | disposed(M) | 19.2K | — | $0 |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Sell(S) | 19.2K | $242.99 | $4.7M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | acquired(M) | 33.4K | $131.94 | $4.4M |
| Feb 17, 2026 | Swanson James D. | EVP, CIO | acquired(M) | 20.5K | $164.62 | $3.4M |
| Feb 17, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell(S) | 6.2K | $243.39 | $1.5M |
| Feb 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | acquired(M) | 29.9K | $156.15 | $4.7M |
| Feb 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell(S) | 29.9K | $243.00 | $7.3M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Sell(S) | 12.1K | $242.87 | $2.9M |
| Feb 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | acquired(A) | 27.1K | — | $0 |
| Feb 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | disposed(M) | 961 | — | $0 |
| Feb 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | acquired(A) | 1.9K | — | $0 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | acquired(A) | 16.9K | — | $0 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | disposed(M) | 635 | — | $0 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | disposed(M) | 606 | — | $0 |
| Feb 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | acquired(M) | 1.1K | — | $0 |
| Feb 15, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | acquired(M) | 1.6K | — | $0 |
| Feb 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | acquired(A) | 3.5K | — | $0 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | acquired(A) | 1.2K | — | $0 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | disposed(F) | 325 | $243.45 | $79K |
| Feb 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | disposed(F) | 544 | $243.45 | $132K |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | acquired(M) | 492 | — | $0 |
| Feb 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | disposed(M) | 1.1K | — | $0 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | acquired(M) | 635 | — | $0 |
| Feb 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | acquired(M) | 961 | — | $0 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | disposed(F) | 310 | $243.45 | $75K |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | acquired(M) | 606 | — | $0 |
| Feb 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | disposed(M) | 1.8K | — | $0 |
| Feb 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | disposed(M) | 1.3K | — | $0 |
| Feb 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | acquired(A) | 49.4K | — | $0 |
| Feb 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | disposed(F) | 492 | $243.45 | $120K |
| Feb 15, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | disposed(F) | 816 | $243.45 | $199K |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | acquired(A) | 1.4K | — | $0 |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | disposed(M) | 1.9K | — | $0 |
| Feb 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | disposed(F) | 528 | $243.45 | $129K |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | disposed(M) | 2.0K | — | $0 |
| Feb 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | disposed(F) | 385 | $243.45 | $94K |
| Feb 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | acquired(M) | 1.8K | — | $0 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | acquired(A) | 19.4K | — | $0 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | disposed(M) | 709 | — | $0 |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | disposed(F) | 817 | $243.45 | $199K |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | acquired(M) | 1.9K | — | $0 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | disposed(M) | 492 | — | $0 |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | disposed(F) | 858 | $243.45 | $209K |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | acquired(M) | 2.0K | — | $0 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | disposed(F) | 214 | $243.45 | $52K |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | disposed(M) | 339 | — | $0 |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | disposed(M) | 344 | — | $0 |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | acquired(A) | 4.9K | — | $0 |
| Feb 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | acquired(A) | 20.3K | — | $0 |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | acquired(M) | 344 | — | $0 |
| Feb 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | acquired(A) | 1.5K | — | $0 |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | acquired(A) | 53.8K | — | $0 |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | acquired(A) | 3.9K | — | $0 |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | disposed(F) | 95 | $243.45 | $23K |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | acquired(A) | 700 | — | $0 |
| Feb 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | disposed(M) | 575 | — | $0 |
| Feb 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | disposed(M) | 419 | — | $0 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | disposed(F) | 309 | $243.45 | $75K |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | acquired(M) | 709 | — | $0 |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | acquired(M) | 339 | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S) — the tradeable signal; awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).